Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-08-15
2002-05-07
Fan, Jane (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S273700
Reexamination Certificate
active
06384059
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a novel crystalline form of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1
H
-benzimidazole 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1
H
-benzimidazole is known under the generic name omeprazole and its novel crystalline form is hereinafter referred to as omeprazole form A. Further, the present invention also relates to use of omeprazole form A for the treatment of gastrointestinal disorders, pharmaceutical compositions containing omeprazole form A and processes for the preparation of omeprazole form A.
BACKGROUND OF THE INVENTION PRIOR ART
The compound 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1
H
-benzimidazole, having the generic name omeprazole, as well as therapeutically acceptable salts thereof, are described in EP 5129. The single crystal X-ray data and the derived molecular structure of the so far only known crystal form of omeprazole is described by Ohishi et al., Acta Cryst. (1989), C45, 1921-1923. This published crystal form of omeprazole is hereinafter referred to as omeprazole form B.
Omeprazole is a proton pump inhibitor, i.e. effective in inhibiting gastric acid secretion, and is useful as an antiulcer agent. In a more general sense, omeprazole may be used for treatment of gastric-acid related diseases in mammals and especially in man.
REFERENCES:
patent: 4337257 (1982-06-01), Junggren et al.
patent: 4738974 (1988-04-01), Brändström
patent: 5314506 (1994-05-01), Midler et al.
patent: 5690960 (1997-11-01), Bengtsson et al.
patent: 5714505 (1998-02-01), Hasselkus
patent: 5856493 (1999-01-01), Ward et al.
patent: 5877192 (1999-03-01), Lindberg et al.
patent: 5900424 (1999-05-01), Källstrom et al.
patent: 5129 (1981-04-01), None
patent: 533752 (1992-06-01), None
patent: 9722603 (1997-06-01), None
patent: 9821201 (1998-05-01), None
patent: 9925711 (1999-05-01), None
Cairns et al., Journal of Chromatography,. “Enantioselective high performance liquid chromatographic determination of omeprazole in human plasma”, pp. 323-328 (1995).
Erlandsson et al., Journal of Chromatography, “Resolution of the enantiomers of omeprazole and some analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase; The effect of the enantiomers of omeprazole on gastric glands”, pp. 305-319 (1990).
Ohishi et al., “Structure of 5-Methoxy-2-{[-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny}-1H-benzimidazole (Omeprazole)”, pp. 1921-1323 (1989).
Heneck et al., “Polymorphie von Arzneistoffen”, Pharm. Ind., 59, 1997, 165-169 CN 1160050.
Brändström, A. et al., “Structure activity relationships of substituted benzimidazoles”, Scandinavian Journal of Gastroenterology, 20: Supplemental 108, 15-22 (1985).
Lövqvist Karin
Noreland David
Sunden Gunnel
Ymen Ingvar
AstraZëneca AB
Fan Jane
White & Case LLP
LandOfFree
Crystalline form of omeprazole does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline form of omeprazole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline form of omeprazole will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2899528